Glaukos (NYSE:GKOS) Price Target Lowered to $104.00 at BTIG Research

Glaukos (NYSE:GKOS) had its price target cut by BTIG Research from $118.00 to $104.00 in a report published on Monday, Marketbeat Ratings reports. They currently have a buy rating on the medical instruments supplier’s stock.

A number of other research firms also recently commented on GKOS. Wells Fargo & Company boosted their target price on shares of Glaukos from $86.00 to $92.00 and gave the stock an “equal weight” rating in a report on Thursday, July 31st. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a report on Thursday, July 31st. Zacks Research downgraded shares of Glaukos from a “strong-buy” rating to a “hold” rating in a report on Friday, August 15th. Truist Financial dropped their target price on shares of Glaukos from $126.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Finally, UBS Group boosted their target price on shares of Glaukos from $125.00 to $134.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $116.92.

Glaukos Stock Up 0.7%

GKOS stock opened at $83.11 on Monday. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. The firm’s 50-day moving average is $87.86 and its two-hundred day moving average is $92.48. Glaukos has a 52 week low of $77.10 and a 52 week high of $163.71. The company has a market capitalization of $4.77 billion, a price-to-earnings ratio of -50.37 and a beta of 0.76.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business had revenue of $124.12 million for the quarter, compared to the consensus estimate of $115.49 million. During the same period in the previous year, the firm earned ($0.52) EPS. The business’s revenue for the quarter was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. On average, analysts forecast that Glaukos will post -1.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GKOS. Bessemer Group Inc. lifted its stake in Glaukos by 133.9% in the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 158 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in shares of Glaukos by 72.9% in the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 159 shares during the last quarter. Park Place Capital Corp lifted its stake in shares of Glaukos by 68.4% in the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 162 shares during the last quarter. AlphaQuest LLC lifted its stake in shares of Glaukos by 5,754.5% in the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after buying an additional 633 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Glaukos by 16.2% in the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 136 shares during the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.